

Express Mail:EV416037106US
Date Deposited: 09/29/2006



Page 1 of 2

Substitute for form 1449A/PTO

**2nd SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Complete if Known	
Application Number	10/774,242
Filing Date	02/06/2004
First Named Inventor	Patrick A. McKee et al.
Group Art Unit	1653 (conf. No. 8624)
Examiner Name	Hope A. Robinson
Attorney Docket Number	5820.646

U. S. PATENT DOCUMENTS						
EXAM INIT.	Cite No. 1	U.S. PATENT NUMBER Number	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
EXAM INIT.	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office 3	Number 4	Kind Code ⁵ (if known)				
			EP 04 70 9157		McKee (Supplementary EPO Search Report)	08/16/2006		
			WO 97/34927 A		Zimmerman et al. (Ludwig Institute for Cancer Research)	09/27/1997		

U.S. and Foreign: ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴Form Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

EXAM INIT.	PATENT DOCUMENTS
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	FOEKENS ET AL., "The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer", <i>Cancer Research</i> , Vol. 63, No. 2 (Jan. 15, 2003) pp. 337-341. (XP-002394318)

EXAM INIT.		<p align="center">PATENT DOCUMENTS</p> <p align="center">Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</p>
H		LEE ET AL., "A novel plasma proteinase potentiates α_2 -antiplasmin inhibition of fibrin digestion", <i>Blood</i> , Vol. 103, No. 10 (May 15, 2004) pp. 3783-3788. (XP-002394321)
		LEE ET AL., "Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein", <i>Blood</i> , Vol. 107, No. 4 (Feb. 15, 2006) pp. 1397-1404. (XP-002394322)
		PARK ET AL., "Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fobroblasts", <i>Journal of Biological Chemistry</i> , Vol. 274, No. 51 (Dec. 17, 1999) pp. 36505-36512. (XP-002163938)
V		URANO ET AL., "The cleavage and inactivation of plasminogen activator inhibitor type 1 and α_2 -antiplasmin by reptilase, a thrombin-like venom enzyme", <i>Blood Coagulation and Fibrinolysis 2000</i> , Vol. 11, No. 2 (March 2000) pp. 145-153. (XP009071038)
Non Patent Documents: ¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.		
Examiner Signature: 	Date Considered: 11/11/06	
EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. **Place of Publication refers to name of publication in which the information was published.		